Belantamab
As of the edition of 20 October 2026, Belantamab is an antibody: marketed, first approved in 2025 (CH); acts on TNFRSF17.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Antibody
- Brand name
- Blenrep
- First approved
- 19 June 2025 (CH)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- GSK
- Registered trials
- 3, 1 stopped early
- Disease areas
- Immune system; Blood and lymph; Cancer; Heart and blood vessels; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TNFRSF17 | Tumor necrosis factor receptor superfamily member 17 | Q02223 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 0 | 1 | 1 |
| Phase 2 | 1 | 0 | 1 | 0 |
| All trials | 3 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| GSK | Applicant and Lead sponsor of trials | 2023 to now |